Harvard University - Massachusetts General Hospital, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, Queen Mary University of London - Wolfson Institute of Population Health, Imperial College London - AGE Research Unit, University College London, Department of Clinical Biochemistry, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), London School of Economics & Political Science (LSE), Create Health Ltd, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Harvard University - Massachusetts General Hospital

University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, Barts Health NHS Trust, Department of Cellular Pathology, Queen Mary University of London - Wolfson Institute of Population Health, Imperial College London - AGE Research Unit, Government of the United Kingdom - Department of Gynaecological Oncology, University College London - Department of Cellular Pathology, Barts Health NHS Trust, Department of Cellular Pathology, University College London, Department of Clinical Biochemistry, Cardiff and Vale University Health Board - Department of Obstetrics and Gynaecology, University of Nottingham - Department of Gynaecological Oncology, University College London - MRC Clinical Trials Unit, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), London School of Economics & Political Science (LSE), Create Health Ltd, Harvard University - Massachusetts General Hospital, University College London - MRC Clinical Trials Unit and University College London - MRC Clinical Trials Unit